CN1426783A - Application of evodiamine in the preparation of medicine - Google Patents
Application of evodiamine in the preparation of medicine Download PDFInfo
- Publication number
- CN1426783A CN1426783A CN 01138862 CN01138862A CN1426783A CN 1426783 A CN1426783 A CN 1426783A CN 01138862 CN01138862 CN 01138862 CN 01138862 A CN01138862 A CN 01138862A CN 1426783 A CN1426783 A CN 1426783A
- Authority
- CN
- China
- Prior art keywords
- rutaecarpin
- total alkali
- tumor
- animals
- matched group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A new application of evodiamine to preparing antineoplastic medicines is disclosed. It has high a curative effect to sarcoma, cervical cancer, liver cancer, etc.
Description
Technical field:
The present invention relates to the purposes of rutaecarpin in pharmaceutical field, relate in particular to the new purposes in the preparation antineoplastic agent.
Background technology:
The disclosed chemical structural formula of rutaecarpin (Evodiamine) is:
Rutaecarpin can make by extracting in the rutaceae Fructus Evodiae.Known this chemical compound has the function of dispersing cold for relieving pain, stopping nausea and vomiting by lowering the adverse flow of QI, supporing yang antidiarrheal.Headache due to JUE YIN disorder, colic of cold type stomachache, the disturbance of lower legs due to pathogenic cold and dampness, abdominal pain during menstruation, abdominal distention, vomiting acid regurgitation be can be used as, external treatment aphtha, vascular hypertension had loose bowels just before dawn.
Summary of the invention:
The object of the present invention is to provide the purposes in the new medicine of rutaecarpin.
The present invention relates to the application of rutaecarpin in the preparation antineoplastic agent.
The present invention realizes in the following way.At first be to extract by chemical method to obtain the Fructus Evodiae total alkali, divide its dry powder encapsulated then or be equipped with propylene glycol Polyethylene Glycol mixed solution and make injection.Concrete technical scheme is that employing natural plants Fructus Evodiae is a raw material, get alcohol extraction part (promptly soaking paste) with alcohol reflux, extract pure extractum with hydrochloric acid solution, acidic water extract liquid enriching ammonia precipitation process is removed supernatant, the leaching precipitate, precipitate is made the homogenate shape with ammonia, add ammonia and make pulpous state, add chloroform extraction again, leave standstill, separate.Chloroform extracted solution with anhydrous sodium sulfate dehydration, filtration, reclaims chloroform with the normal pressure water-bath, gets the Fructus Evodiae total alkali after drying.
Rutaecarpin separates through the silica gel dry chromatography again, with petroleum ether add ethyl acetate, water carries out eluting, checks various flows part with the thin plate chromatography again, merges with rutaecarpin standard substance Rf value uniform portion, concentrates, chloroform, recrystallizing methanol promptly obtain rutaecarpin.
The experiment proved that: Fructus Evodiae total alkali and U.S. rutaecarpin all have tangible tumor-inhibiting action, and rutaecarpin is the main antitumor active ingredient of Fructus Evodiae total alkali.So in pharmacy procedure,, often directly adopt the Fructus Evodiae total alkali to make antitumor drug from simplifying extraction process.
Getting the Fructus Evodiae total alkali is raw material, sprays with ethanol and makes soft material, sieves, and makes granule, carries out drying again, sieves, and can incapsulate, and becomes Fructus Evodiae total alkali capsule.
The Fructus Evodiae total alkali is dissolved in propylene glycol, in the Polyethylene Glycol mixed liquor, fully stir and add an amount of water for injection, filter can make Fructus Evodiae total alkali injection to clear and bright.
In order to understand essence of the present invention better, to use the Fructus Evodiae total alkali below, rutaecarpin, the antitumor test and the result of rutaecarpine and Fructus Evodiae lactone illustrate the antitumor action of its Fructus Evodiae total alkali and rutaecarpin, thereby its new purposes in the preparation antineoplastic agent is described.
Method: adopt 4 kinds of mice transplanted tumors, i.e. S-180 (S-180), mouse cervical cancer-14 (U
14), liver ascites (HepA) and ehrlich carcinoma (EAC).Experiment mice is divided into matched group at random, SC normal saline 10mlkg
-1, cyclophosphamide (ip15mgkg
-1), total alkali (sc96,48 and 24mgkg
-1), rutaecarpin (sc40,20 and 10mgkg
-1) rutaecarpine (sc50,25mg.kg
-1) and obaculactone (sc56,28mg.kg
-1); Each tests medicine sc volume is 10ml.kg
-1Choose the transplantation tumor well-grown, abdominal tympanites is little mice obviously, the skin of abdomen sterilization, thrust the abdominal cavity with disposable sterilized hemostix through stomach wall, extract ascites, put into aseptic beaker is diluted to 1: 3 with normal saline cancerous cell suspension, in the right oxter inoculation of every experiment mice 0.2ml, each treated animal begins administration, every day 1 time, successive administration 10 days in inoculated tumour next day.Administration finishes next day, and dislocation was put to death after animal was weighed, and separated subcutaneous lump and weighed, and respectively organized the tumor growth situation, and each is organized, and tumor is heavy uses " t " check to measure with the matched group significance of difference.
Each treated animal body weight, tumor weight and tumour inhibiting rate statistical result see Table 1-12.
Table 1 total alkali (sc) is to mice S
180The influence that tumor weighs (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 20.3 ± 1.25 27.2 ± 3.29 1.32 ± 0.32 cyclophosphamide 15 10 19.7 ± 1.42 25.2 ± 1.14 0.75 ± 0.32 after the administration before the administration
* *51.5 total alkali is high by 96 10 19.6 ± and 1.43 26.3 ± 2.45 0.78 ± 0.42
* *43.2 in the total alkali 48 10 19.7 ± 1.25 26.9 ± 2.51 0.78 ± 0.42
*40.9 total alkali low 24 10 19.3 ± 0.95 27.3 ± 3.47 0.94 ± 0.43
*28.8 annotate: compare * p＜0.05:**p＜0.01 with matched group; * * p＜0.001
Table 2 total alkali (sc) is to mice U
14The influence that tumor weighs (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.8 ± 1.48 27.0 ± 3.80 1.54 ± 0.57 cyclophosphamide 15 10 20.1 ± 1.45 25.0 ± 1.56 0.69 ± 0.27 after the administration before the administration
* *55.2 total alkali is high by 96 10 19.2 ± and 1.14 26.2 ± 3.05 0.74 ± 0.48
*51.9 in the total alkali 48 10 20.0 ± 1.56 27.2 ± 3.12 0.84 ± 0.38
*45.5 total alkali low 24 10 20.3 ± 0.95 27.9 ± 3.54 1.03 ± 0.47
*33.1 annotate: compare * p＜0.05 with matched group; * p＜0.01:***p＜0.001
The influence that table 3 total alkali (sc) is heavy to mice HepA tumor (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 20.2 ± 1.48 27.8 ± 4.05 1.98 ± 0.94 cyclophosphamide 15 10 19.8 ± 1.32 25.6 ± 1.08 0.71 ± 0.21 after the administration before the administration
* *64.1 total alkali is high by 96 10 19.5 ± and 1.35 26.9 ± 2.13 0.79 ± 0.41
*60.1 in the total alkali 48 10 19.6 ± 1.35 27.9 ± 3.73 1.10 ± 0.51
*44.4 total alkali low 24 10 19.2 ± 1.32 27.1 ± 4.01 1.21 ± 0.67
*38.9 annotate: compare * p＜0.05 with matched group; * p＜0.01; * * p＜0.001
The influence that table 4 total alkali (sc) is heavy to mice EAC tumor (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.5 ± 1.35 27.6 ± 3.57 1.56 ± 0.52 cyclophosphamide 15 10 19.4 ± 1.27 24.9 ± 1.20 0.57 ± 0.20 after the administration before the administration
* *63.5 total alkali is high by 96 10 19.9 ± and 1.60 25.8 ± 1.32 0.69 ± 0.28
* *55.8 in the total alkali 48 10 19.4 ± 1.58 27.0 ± 2.79 0.91 ± 0.46
*41.7 total alkali low 24 10 19.5 ± 1.35 26.6 ± 2.84 1.04 ± 0.45
*33.3 annotate: compare * p＜0.05 with matched group; * p＜0.0 1; * * p＜0.001
Table 5 rutaecarpin (sc) is to mice S
180The influence that tumor weighs (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 20.5 ± 1.08 28.2 ± 3.33 1.79 ± 0.7 cyclophosphamide 15 10 20.3 ± 1.42 24.8 ± 1.40 0.67 ± 0.16 after the administration before the administration
* *62.6 rutaecarpin 40 10 20.0 ± 1.33 25.7 ± 1.64 0.71 ± 0.19
* *60.3 rutaecarpin 20 10 19.9 ± 1.60 25.5 ± 3.03 0.92 ± 0.37
*48.6 rutaecarpin 10 10 19.9 ± 1.45 26.7 ± 1.89 1.16 ± 0.49
*35.2 annotate: compare * p＜0.05 with matched group; * p＜0.01; * * p＜0.001
Table 6 rutaecarpin (sc) is to mice U
14The influence that tumor weighs (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.9 ± 1.37 27.6 ± 3.89 1.58 ± 0.54 cyclophosphamide 15 10 20.1 ± 1.60 25.2 ± 1.32 0.53 ± 0.09 after the administration before the administration
* *66.5 rutaecarpin 40 10 19.8 ± 1.14 25.0 ± 1.81 0.68 ± 0.36
* *57.0 rutaecarpin 20 10 19.8 ± 1.40 26.0 ± 2.06 0.85 ± 0.46
*46.2 rutaecarpin 10 10 20.0 ± 1.49 26.2 ± 2.78 1.01 ± 0.46
*36.1 annotate: compare * p＜0.05 with matched group; * p＜0.01; * * p＜0.001
The influence that table 7 rutaecarpin (sc) is heavy to mice HepA tumor (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 20.5 ± 1.35 27.5 ± 3.17 1.69 ± 0.60 cyclophosphamide 15 10 19.5 ± 1.18 24.8 ± 1.23 0.60 ± 0.18 after the administration before the administration
* *64.5 rutaecarpin 40 10 19.8 ± 1.23 26.4 ± 1.96 0.81 ± 0.52
*52.1 rutaecarpin 20 10 19.8 ± 1.14 25.9 ± 2.92 0.99 ± 0.45
*41.4 rutaecarpin 10 10 19.9 ± 1.52 26.8 ± 3.68 1.12 ± 0.57
*33.7 annotate: compare * p＜0.05 with matched group; * p＜0.01; * * p＜0.001
The influence that table 8 rutaecarpin (sc) is heavy to mice EAC tumor (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.8 ± 1.22 27.3 ± 2.31 1.54 ± 0.40 cyclophosphamide 15 10 19.9 ± 1.37 25.5 ± 1.08 0.67 ± 0.26 after the administration before the administration
* *65.5 rutaecarpin 40 10 19.9 ± 1.52 27.3 ± 3.40 0.84 ± 0.35
* *45.6 rutaecarpin 20 10 19.6 ± 1.43 26.0 ± 1.89 0.93 ± 0.52
*39.6 rutaecarpin 10 10 20.0 ± 1.49 26.4 ± 3.63 1.04 ± 0.45
*32.5 annotate: compare * p＜0.05 with matched group; * p＜0.0 1; * * p＜0.001
Table 9 rutaecarpine, lactone (sc) are to mice S
180The influence that tumor weighs (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.9 ± 1.45 28.1 ± 3.60 1.44 ± 0.60 cyclophosphamide 15 10 20.0 ± 1.49 25.4 ± 1.35 0.59 ± 0.15 after the administration before the administration
* *59.0 rutaecarpine 50 10 19.9 ± 1.45 27.0 ± 1.94 1.08 ± 0.37
*31.9 rutaecarpine 25 10 20.1 ± 1.37 25.9 ± 1.73 1.04 ± 0.24
#27.8 obaculactone 56 10 19.5 ± 1.35 25.6 ± 1.17 1.14 ± 0.21
#28.5 obaculactone 28 10 19.6 ± 1.08 26.5 ± 1.43 1.09 ± 0.29
#24.3 annotate: compare #p＞0.05:*p＜0.05:***p＜0.001 with matched group
Table 10 rutaecarpine, lactone (sc) are to mice U
14The influence that tumor weighs (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.9 ± 1.45 26.7 ± 2.41 1.51 ± 0.48 cyclophosphamide 15 10 20.0 ± 1.65 25.5 ± 1.65 0.77 ± 0.26 after the administration before the administration
*49.0 rutaecarpine 50 10 19.6 ± 0.21 25.8 ± 1.99 1.06 ± 0.28
*29.8 rutaecarpine 25 10 20.0 ± 1.99 26.4 ± 1.90 1.16 ± 0.30
#23.2 obaculactone 56 10 19.8 ± 1.32 26.1 ± 2.08 1.08 ± 0.39
*28.5 obaculactone 28 10 19.5 ± 1.65 26.8 ± 2.97 1.22 ± 0.
#19.2 annotate: compare #p＞0.05:*p＜0.05 with matched group; * p＜0.01
The influence that table 11 rutaecarpine, lactone (sc) weigh mice HepA tumor (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.5 ± 1.35 26.3 ± 1.95 1.38 ± 0.56 cyclophosphamide 15 10 20.0 ± 1.49 24.8 ± 1.23 0.63 ± 0.13 after the administration before the administration
* *56.5 rutaecarpine 50 10 19.6 ± 1.43 26.2 ± 2.20 1.08 ± 0.19
#21.7 rutaecarpine 25 10 20.1 ± 1.37 26.9 ± 2.73 1.12 ± 0.36
#18.8 obaculactone 56 10 19.4 ± 1.35 26.3 ± 2.58 1.15 ± 0.30
#16.7 obaculactone 28 10 20.2 ± 1.48 25.7 ± 1.34 1.23 ± 0.29
#10.9 annotate: compare #p＞0.05 with matched group; * * p＜0.001
The influence that table 12 rutaecarpine, lactone (sc) weigh mice EAC tumor (X ± S)
The heavy tumour inhibiting rate group of dosage number of animals the weight of animals (g) tumor
Mg.kg
-1(n) (g) (%) matched group-10 19.5 ± 1.35 26.8 ± 2.20 1.37 ± 0.59 cyclophosphamide 15 10 19.8 ± 1.55 25.1 ± 1.79 0.66 ± 0.19 after the administration before the administration
* *51.8 rutaecarpine 50 10 20.5 ± 1.18 25.8 ± 1.48 1.05 ± 0.24
#23.4 rutaecarpine 25 10 20.1 ± 1.45 26.8 ± 2.82 1.12 ± 0.38
#18.2 obaculactone 56 10 19.7 ± 1.42 26.0 ± 2.00 1.15 ± 0.23
#16.2 obaculactone 28 10 20.0 ± 1.16 25.1 ± 1.37 1.17 ± 0.29
#14.6 annotate: compare #p＞0.05 with matched group; * * p＜0.001
Above-mentioned experimentation conclusion shows: total alkali and rutaecarpin have obvious antineoplastic, make antitumor drug with total alkali and rutaecarpin, will play significant inhibition, therapeutical effect to various tumor diseases.
The above results shows, the invention has the advantages that the compound known rutaecarpin has been excavated new medical application, opened up a new application, made antitumor drug with rutaecarpin as the total alkali of active ingredient and have and stronger press down tumor function and antitumor action, and when rutaecarpin is prepared into antitumor drug, its pharmaceutical technology is simple, be convenient to operation, its pharmaceutical dosage form also can be various, can make injection, also can make oral tablet, capsule formulation etc., medication is convenient.
Specific embodiment:
At first extract the raw material that the Fructus Evodiae total alkali is a preparation.Get the Fructus Evodiae crude drug, with 7 times of amount concentration is twice of 80% alcohol reflux, ethanol is reclaimed, alcohol extraction part (soaking paste), extract pure extractum twice with 2% HCL solution again, leave standstill, filter, precipitate with ammonia alkalization extracting solution, remove supernatant, the ammonia of precipitate adding 10% is made the homogenate shape, and with chloroform extraction, it is static to utilize transit mixer to stir after 30 minutes.Combined chloroform liquid is isolated slurry, with the chloroform extracted solution anhydrous sodium sulfate dehydration, filters, and removes sodium sulfate, stays chloroform solution, reclaims chloroform by normal pressure water-bath mode, and the chloroform of recovery stays does reuse, stay the excess drying after, be the Fructus Evodiae total alkali.If intending with the rutaecarpin is raw material, then need carry out following steps again.
The Fructus Evodiae total alkali adds the silica gel of 200 times of amounts and adorns dried post, carry out eluting with petroleum ether, ethyl acetate and water (its ratio is: 10: 5: 1), check various flows part with TLC again, merge and rutaecarpin standard substance Rf value uniform portion, concentrate, the chloroform methanol recrystallization extract at last rutaecarpin.
The preparation of Fructus Evodiae total alkali capsule:
Prescription: Fructus Evodiae total alkali 210g, make 1000 of capsules
Method for making: get Fructus Evodiae total alkali crude drug 210g, spray with an amount of 95% ethanol and make soft material, sieve, make granule, 80 ℃ of following condition dryings are sieved, and in the zero capsule of packing into, packing promptly.
The preparation of Fructus Evodiae total alkali injection:
Prescription: Fructus Evodiae total alkali 50g, propylene glycol 250g, Polyethylene Glycol 250g adds injection water 4000ml, makes 2000.
Method for making: precision takes by weighing 50.0g Fructus Evodiae total alkali, each 250g of propylene glycol and Polyethylene Glycol, with propylene glycol and Polyethylene Glycol mix homogeneously, on water-soluble, be heated to 80 ℃ earlier, 50g Fructus Evodiae total alkali is added propylene glycol, in the Polyethylene Glycol mixed liquor, fully stir, medicinal liquid is dissolved fully, again that preheating is good water for injection (80 ℃) is added in the medicinal liquid lentamente, with playing sonicated 5 minutes, be placed into room temperature.Use G
4The funnel sucking filtration.Embedding is in 2ml peace bottle.Sterilization.Packing, typewriting can be finished the preparation of Fructus Evodiae total alkali injection.
Claims (1)
- The application of rutaecarpin in antitumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01138862 CN1426783A (en) | 2001-12-18 | 2001-12-18 | Application of evodiamine in the preparation of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01138862 CN1426783A (en) | 2001-12-18 | 2001-12-18 | Application of evodiamine in the preparation of medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1426783A true CN1426783A (en) | 2003-07-02 |
Family
ID=4674814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01138862 Pending CN1426783A (en) | 2001-12-18 | 2001-12-18 | Application of evodiamine in the preparation of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1426783A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101787025A (en) * | 2010-03-04 | 2010-07-28 | 中国人民解放军第二军医大学 | Substituted-evodiamine anti-tumor and antifungal compounds and preparation method thereof |
| CN101862334A (en) * | 2010-06-11 | 2010-10-20 | 浙江大学 | Application of evodiamine in preparation of preparation for resisting white spot syndromevirus |
| CN102688242A (en) * | 2011-03-21 | 2012-09-26 | 中国医学科学院医药生物技术研究所 | Novel application of rutaecarpine compound |
| CN106265704A (en) * | 2016-07-26 | 2017-01-04 | 河南大学 | The Traditional Chinese Herb combination of a kind of target tumor hypoxia microenvironment application in oncotherapy |
| CN110537552A (en) * | 2019-08-14 | 2019-12-06 | 广州和香元香文化传播有限公司 | Agilawood nano aromatherapy health-care material and preparation method and application thereof |
| CN111333606A (en) * | 2020-04-20 | 2020-06-26 | 大连医科大学附属第一医院 | Carbon-reducing sesquiterpenoids, preparation method and application as antitumor drugs |
-
2001
- 2001-12-18 CN CN 01138862 patent/CN1426783A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101787025A (en) * | 2010-03-04 | 2010-07-28 | 中国人民解放军第二军医大学 | Substituted-evodiamine anti-tumor and antifungal compounds and preparation method thereof |
| CN101862334A (en) * | 2010-06-11 | 2010-10-20 | 浙江大学 | Application of evodiamine in preparation of preparation for resisting white spot syndromevirus |
| CN102688242A (en) * | 2011-03-21 | 2012-09-26 | 中国医学科学院医药生物技术研究所 | Novel application of rutaecarpine compound |
| CN102688242B (en) * | 2011-03-21 | 2014-08-06 | 中国医学科学院医药生物技术研究所 | Novel application of rutaecarpine compound |
| CN106265704A (en) * | 2016-07-26 | 2017-01-04 | 河南大学 | The Traditional Chinese Herb combination of a kind of target tumor hypoxia microenvironment application in oncotherapy |
| CN110537552A (en) * | 2019-08-14 | 2019-12-06 | 广州和香元香文化传播有限公司 | Agilawood nano aromatherapy health-care material and preparation method and application thereof |
| CN111333606A (en) * | 2020-04-20 | 2020-06-26 | 大连医科大学附属第一医院 | Carbon-reducing sesquiterpenoids, preparation method and application as antitumor drugs |
| CN111333606B (en) * | 2020-04-20 | 2022-05-10 | 大连医科大学附属第一医院 | Carbon-reducing sesquiterpenoids, preparation method and application as antitumor drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN101849999B (en) | Chinese medicinal composition for treating pelvic inflammation and preparation method thereof | |
| CN1425447A (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
| CN1217669C (en) | Naringin used in preparing medicine for curing acute and chronic bronchitis | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN101040891A (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN102406694B (en) | Anti-tumor effective part of traditional Chinese medicine lespedeza as well as preparation method and application thereof | |
| CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN1513497A (en) | Immunity regulation medicine composition, and its prepn. method | |
| CN1839855A (en) | Ginsenoside F1 medicinal uses | |
| CN1421229A (en) | Chinese medicine for treating hepatocirrhosis, hepatitis and liver cancer | |
| CN1053376C (en) | Antineoplastic Chinese medicine prepn and its prepn process | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN104840748B (en) | Chinese medicine composition with anti-cancer of the brain activity and its preparation method and application | |
| CN1424028A (en) | Medicine for treating cancers and use thereof | |
| CN1079396A (en) | Intelligence-enhancing pharmaceutical preparation | |
| CN1834108B (en) | Acanthopanax giraldii Harms compound polysaccharide, preparation technique, uses and its compound polysaccharide composition | |
| CN1167441C (en) | Xiangshen soft capsule and preparation process and use thereof | |
| CN1947715A (en) | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis | |
| CN1148978A (en) | Auricledleaf swallowort for anti-hepatitis, its usage and preparation | |
| CN1491688A (en) | Immune regulator prepared from waste material in preparing Mailuoning injection process and its use in producing medicine | |
| CN1559503A (en) | Mango couth suppressing capsule and method of preparatuion long effect capsule | |
| CN1583728A (en) | Compound extracted from eucalyptus plant and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |